(1)
Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization was published in the
American Journal of Physiology -
Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and
Molecular Stethoscope Announces Completion and Publication of its Alzheimer s Disease Study in Science Advances
Study results highlight the Company s Next-Generation cf-mRNA Liquid Biopsy-Artificial Intelligence Technology Platform for characterization of Alzheimer s Disease
PALO ALTO, Calif., Dec. 14, 2020 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of a human proof-of-concept study for Alzheimer s Disease using its proprietary cell-free messenger RNA (cf-mRNA)-Artificial Intelligence Technology Platform. The study appeared in the December 2020 issue of the American Association for the Advancement of Science journal,
Science Advances. The Technology Platform s dynamic detection and monitoring of dysregulated genes and biological processes in Alzheimer s Disease provides a promising new approach to stratify patients and to follow disease course and targeted intervention, commented James Brewer, M.D., Ph.D., Dire